Citeline Podcasts

On this week's podcast, we discussed a modification to FDA's definition of "intended use," legal patent issues with Boston Scientific’s Lotus valve, the Republican bill to replace the Affordable Care Act and some disappointing clinical trial news that was presented at the annual Society of Interventional Radiology conference.

On this week's podcast, we discussed a modification to FDA's definition of "intended use," legal patent issues with Boston Scientific’s Lotus valve, the Republican bill to replace the Affordable Care Act and some disappointing clinical trial news that was presented at the annual Society of Interventional Radiology conference.

On this week's podcast, we discussed a modification to FDA's definition of "intended use," legal patent issues with Boston Scientific’s Lotus valve, the Republican bill to replace the Affordable Care Act and some disappointing clinical trial news that was presented at the annual Society of Interventional Radiology conference.

Center for Drug Evaluation & Research Director Janet Woodcock discusses her new role as interim director in the Office of New Drugs (OND) following the departure of John Jenkins, an update on the Office of Pharmaceutical Quality (OPQ), accelerating new drug approvals, and orphan drug development.

Center for Drug Evaluation & Research Director Janet Woodcock discusses her new role as interim director in the Office of New Drugs (OND) following the departure of John Jenkins, an update on the Office of Pharmaceutical Quality (OPQ), accelerating new drug approvals, and orphan drug development.

Center for Drug Evaluation & Research Director Janet Woodcock discusses her new role as interim director in the Office of New Drugs (OND) following the departure of John Jenkins, an update on the Office of Pharmaceutical Quality (OPQ), accelerating new drug approvals, and orphan drug development.

This is Compliance 360°, an eight-part podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this fifth installment, former FDA investigations branch director Ricki Chase highlights the agency's top 5 inspection observations found on FDA-483 inspection forms.

This is Compliance 360°, an eight-part podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this fifth installment, former FDA investigations branch director Ricki Chase highlights the agency's top 5 inspection observations found on FDA-483 inspection forms.

This is Compliance 360°, an eight-part podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this fifth installment, former FDA investigations branch director Ricki Chase highlights the agency's top 5 inspection observations found on FDA-483 inspection forms.

Pan-cancer screening test developer Grail bags more than $1bn in funding; Trump bashes US FDA; fight likely in Senate over Seema Verma's appointment to head CMS; "FDA Precheck" floated by agency; a deep-dive look into the surgical robot market.